Articles by Emily Menendez
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
CEUS for the assessment of nccRCC can provide a more sensitive alternative to conventional ultrasound imaging.
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
A recent dose-escalation study has demonstrated the safety and efficacy of cabo/nivo or cabo/nivo/ipi for several GU cancers.
The detection rate in biopsy-naïve men undergoing MRI-targeted transrectal or transperineal biopsy was 59% and 62%.
While postoperative hypofractionated radiotherapy is a common treatment, data focusing on long-term outcomes are scarce.
The standard of care for intermediate to high-risk RCC consists of partial or radical nephrectomy and surveillance.
A recent study that sought to characterize rare kidney tumors has identified novel biomarkers in nccRCC subtypes.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
The signature has been initially validated to improve ccRCC risk stratification and provide better treatment allocation.
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
The use of 89Zr PET/CT and subsequent surgery in patients treated with it demonstrated low radiation exposure levels.
The trial previously demonstrated longer PFS rates with avelumab plus axitinib in patients with PD-L1-positive tumors.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.